More than seven years after first testing its Meniere's disease candidate, Otividex, in patients with the inner ear disorder, Otonomy Inc. is immediately suspending development of the specially formulated steroid after it proved no better than a placebo in reducing both the number and severity of vertigo episodes in the first of two phase III trials.